Amplia appoints leading drug developer as Oncology Clinical Advisor
Posted: 27 October 2021 Amplia Therapeutics has today announced the appointment of internationally renowned drug developer, José Iglesias M.D, as its Oncology Clinical Advisor. Click here to read today’s ASX release Dr Iglesias has over 33 years’ experience in…
AdAlta presentations at AusBiotech invest and BIO-Europe
Posted: 25 October 2021 BioMelbourne Network member, AdAlta Limited, the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased to announce that CEO and Managing Director, Dr Tim Oldham, will present at…
Joint Response to the HERC IP Framework Consultation
Posted: 20 October 2021 Research Australia, Medicines Australia, the Medical Technology Association of Australia (MTAA) and AusBiotech have responded to the HERC IP Framework Consultation paper. Together, they represent a significant proportion of the health R&D sector and…
WEHI and CSL to advance biologic therapies
Posted: 20 October 2021 Two of Melbourne’s most prominent medical research and drug development organisations, WEHI and CSL, have joined forces to create a Centre for Biologic Therapies. The new Centre combines WEHI’s expertise in immunology, cancer, inflammatory…
Brooker Consulting: Interim Executive Specialists
Posted 9 October 2021 Brooker Consulting have announced that Michelle Lyon has joined the team, specialising in interim executive appointments. Michelle has over 15 years’ experience in executive search, firstly partnering with FMCG and consumer-led businesses, then working…
360biolabs opens Brisbane-based specialty lab
Posted: 1 October 2021 Their Brisbane laboratory enables 360biolabs to further support clinical trials in the north-east region of Australia. As Australia’s leading and most comprehensive specialty laboratory, 360biolabs often receives requests to process samples for downstream enzymatic…
World’s first four dimensional post-COVID lung imagery
Posted 29 September 2021 The world’s first four-dimensional visual insight into the residual effects of COVID-19 or ‘long COVID’ providing an unprecedented ability for patients, clinicians and researchers to understand the ongoing impact of this disease has been…
Cancer Therapeutics Unveils New Identity
Posted 29 September 2021 BioMelbourne Network member Cancer Therapeutics (CTx CRC Ltd) has unveiled its new name and brand identity – Canthera Discovery. This transformation forms part of a wider organisational strategy to continue the incredible legacy of…
DMX-200 recommended for regulatory approval in COVID-19 study in India
Posted 27 September 2021 Highlights DCGI review complete and study formally recommended for regulatory approval Multiple clinical sites in India initiated Study protocol to recruit 600 participants with COVID-19 overall, with a safety analysis conducted after the first…
AdAlta Granted R&D Rebate funding Facility with Invest Victoria
Posted 22 September 2021 AdAlta granted A$4.0m non-dilutive R&D Rebate funding Facility with Invest Victoria. Facility is one of the first of its kind from Victorian Government. Facility relates to FY2022 R&D and is in addition to existing…
New Swinburne hub co-creating the medical technologies of the future
Posted: 10 September 2021 MedTechVic will bring people with disabilities together with world-leading technology and expertise to create life-changing new medical and enabling technologies. MedTechVic will create the Australian Assistive Technology Living Facility (LivingAT) on Swinburne’s Hawthorn campus,…
SYNthesis Research announces Chief Innovation Officer
Posted 1 September 2021 SYNthesis Research has announced that Dr Martine Keenan will be joining as Chief Innovation Officer. Martine brings to the role exceptional national and international experience in translational drug discovery & development, and the reputation…
